Survodutide vs Tirzepatide
A dual glucagon and GLP-1 receptor agonist — the co-agonist that skips GIP and aims at the liver. A dual GIP and GLP-1 receptor agonist — the first of the co-agonists. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Survodutide BI 456906 | Tirzepatide | |
|---|---|---|
| Also known as | — | Mounjaro, Zepbound |
| Type | Analog | Analog |
| Evidence | Investigational | Established |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | Glucagon/GLP-1 dual receptor agonist (acylated peptide) | Dual GIP/GLP-1 receptor agonist (39 aa, acylated) |
| Receptor / target | Glucagon receptor (GCGR) + GLP-1 receptor | GIP receptor + GLP-1 receptor |
| Molecular weight | ≈4,800 Da | ~4,813.5 Da |
| Half-life | engineered for once-weekly dosing | |
| Based on | Glucagon-like peptide-1 | Glucose-dependent insulinotropic polypeptide |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Survodutide and Tirzepatide?
- Survodutide is an engineered analog based on Glucagon-like peptide-1; Tirzepatide is an engineered analog based on Glucose-dependent insulinotropic polypeptide. Survodutide signals at Glucagon receptor (GCGR) + GLP-1 receptor; Tirzepatide signals at GIP receptor + GLP-1 receptor.
- How do the half-lives of BI 456906 and Tirzepatide compare?
- The reported circulating half-life of Survodutide is engineered for once-weekly dosing; Tirzepatide is ~5 days (~120 h). These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Tirzepatide vs Survodutide. Or open the interactive comparison tool to add more molecules.